Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan 11;481(7381):329-34.
doi: 10.1038/nature10733.

A novel retinoblastoma therapy from genomic and epigenetic analyses

Jinghui Zhang  1 , Claudia A Benavente, Justina McEvoy, Jacqueline Flores-Otero, Li Ding, Xiang Chen, Anatoly Ulyanov, Gang Wu, Matthew Wilson, Jianmin Wang, Rachel Brennan, Michael Rusch, Amity L Manning, Jing Ma, John Easton, Sheila Shurtleff, Charles Mullighan, Stanley Pounds, Suraj Mukatira, Pankaj Gupta, Geoff Neale, David Zhao, Charles Lu, Robert S Fulton, Lucinda L Fulton, Xin Hong, David J Dooling, Kerri Ochoa, Clayton Naeve, Nicholas J Dyson, Elaine R Mardis, Armita Bahrami, David Ellison, Richard K Wilson, James R Downing, Michael A Dyer
Affiliations

A novel retinoblastoma therapy from genomic and epigenetic analyses

Jinghui Zhang et al. Nature. .

Abstract

Retinoblastoma is an aggressive childhood cancer of the developing retina that is initiated by the biallelic loss of RB1. Tumours progress very quickly following RB1 inactivation but the underlying mechanism is not known. Here we show that the retinoblastoma genome is stable, but that multiple cancer pathways can be epigenetically deregulated. To identify the mutations that cooperate with RB1 loss, we performed whole-genome sequencing of retinoblastomas. The overall mutational rate was very low; RB1 was the only known cancer gene mutated. We then evaluated the role of RB1 in genome stability and considered non-genetic mechanisms of cancer pathway deregulation. For example, the proto-oncogene SYK is upregulated in retinoblastoma and is required for tumour cell survival. Targeting SYK with a small-molecule inhibitor induced retinoblastoma tumour cell death in vitro and in vivo. Thus, retinoblastomas may develop quickly as a result of the epigenetic deregulation of key cancer pathways as a direct or indirect result of RB1 loss.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Characterization of retinoblastomas samples
a–c, Representative retinoblastoma tumor section(SJRB001) stained with hematoxylin and eosin (H&E) showing choroidal and optic nerve invasion (arrow). d–f, H&E-stained section of the SJRB001X orthotopic xenograft with choroidal (e) and optic nerve (f) invasion (arrows). Abbreviations: AC, anterior chamber; ON, optic nerve; Sc, sclera. Scale bars: 25 µm.
Figure 2
Figure 2. Genomic profiles of SJRB001-2 and SJRB001X
a,b, CIRCOS plots of genetic alterations in 2 retinoblastomas and the matched orthotopic xenograft. Loss of heterozygosity (orange), amplifications (red), and deletions (blue) are shown. Interchromosomal translocations (green lines) and intrachromosomal translocations (purple lines) are indicated. Sequence mutations in Refseq genes included silent single nucleotide variants (SNVs, green), missense SNVs (brown), nonsense SNVs (dark blue), splice-site mutations (pink), and insertion/deletion mutations (indels, red). c) BCOR mutations identified in the recurrency cohort.
Figure 3
Figure 3. Analysis of aneuploidy and CIN in retinoblastoma
a, Chromosomal missegregation of SJRB001X cells after at least 21 rounds of cell division is plotted in red. b, Representative SKY image of SJRB001X after the third passage in mice. c, Alterations in the 46 Rb cases (Rb) compared to 153 high-grade serous ovarian cancer (Ov) from TGCA. The median chromosomal lesions for retinoblastoma (Rb) was 1.5% and 27.7% for ovarian cancer (Ov).
Figure 4
Figure 4. SYK Is Expressed in Retinoblastoma and Is Required for Survival
a, Whole-genome view of the gene ranks based on integrating ChIP-on-chip, methylation, and gene expression results. Y-axis is –log(p), where p is a p-value of Q-statistic corrected for multiple testing. Significantly (FDR ≤10%) downregulated (green) or upregulated (red) genes are shown. b, c, ChIP validation of histone markers of the SYK promoter including quantification by quantitative PCR (qPCR) with TaqMan probes. Each bar is the mean and standard deviation of triplicate samples. d, SYK gene expression measured by qPCR in fetal week 20 retina (fetal), primary retinoblastoma (tumor), orthotopic xenografts (SJRB001X and SJRB002X) and cell lines. Each bar is the mean and standard deviation of duplicate samples normalized to GPI1 expression. e, Immunoblot of SYK (green) and actin (red) in orthotopic xenografts, human fetal retina, and representative cell lines; black and white representation of the SYK immunoblot is in the lower panel. f, H&E (purple) and anti-SYK (brown) immunohistochemistry of retinoblastoma tissue. g, Immunoprecipitation analysis of SYK and pSYK Y525/526 from Weri1 retinoblastoma cells. h, Viability was measured in triplicate cultures 72 hours after infection of retinoblastoma cells with a lentivirus vector expressing either a control lentivirus or an shRNA against SYK. Scale bars: 10 µm.
Figure 5
Figure 5. Retinoblastoma Cells are Sensitive to SYK Inhibitors
a, Dose response for SYK inhibitors R406 (red) and BAY 61-3606 (black) in RB355 retinoblastoma cells and a negative control (Jurkat). Each data point is the mean and standard deviation of triplicate samples. b–e Immunofluorescence of activated caspase 3 or EdU(red) before and after treatment of RB355 cells with R406 or BAY 61–3606. A total of 250 cells were scored in duplicate for each sample and each treatment condition to derive the mean and standard deviation. Nuclei were stained with DAPI (blue). f, Treatment of stimulated Jurkat or RB355 cells with 5 µM BAY 61–3606 for 24 hours reduced MCL1 expression. g, Schematic of the treatment schedule for mice with SJRB001X tumors. h, Representative MR images of a mouse whose tumor responded after 4 courses of treatment with BAY 61–3606 (left) and another whose disease progressed during treatment (right). i, Survival curves show that BAY 61–3606+TPT treatment improved outcome. j, Immunostaining for activated caspase 3 (arrows) in untreated or BAY 61–3606–treated eyes. k, untreated or BAY 61-3606–treated eyes. k, Immunoblot showing reduced MCL1 protein after BAY 61–3606 or BAY 61–3606+TPT treatment. Scale bars b, d: 5 µm; j: 10 µm.
See this image and copyright information in PMC

Comment in

Similar articles

  • RB1 gene inactivation by chromothripsis in human retinoblastoma.
    McEvoy J, Nagahawatte P, Finkelstein D, Richards-Yutz J, Valentine M, Ma J, Mullighan C, Song G, Chen X, Wilson M, Brennan R, Pounds S, Becksfort J, Huether R, Lu C, Fulton RS, Fulton LL, Hong X, Dooling DJ, Ochoa K, Mardis ER, Wilson RK, Easton J, Zhang J, Downing JR, Ganguly A, Dyer MA. McEvoy J, et al. Oncotarget. 2014 Jan 30;5(2):438-50. doi: 10.18632/oncotarget.1686. Oncotarget. 2014. PMID: 24509483 Free PMC article.
  • Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies.
    Rushlow DE, Mol BM, Kennett JY, Yee S, Pajovic S, Thériault BL, Prigoda-Lee NL, Spencer C, Dimaras H, Corson TW, Pang R, Massey C, Godbout R, Jiang Z, Zacksenhaus E, Paton K, Moll AC, Houdayer C, Raizis A, Halliday W, Lam WL, Boutros PC, Lohmann D, Dorsman JC, Gallie BL. Rushlow DE, et al. Lancet Oncol. 2013 Apr;14(4):327-34. doi: 10.1016/S1470-2045(13)70045-7. Epub 2013 Mar 13. Lancet Oncol. 2013. PMID: 23498719
  • Cross-species genomic and epigenomic landscape of retinoblastoma.
    Benavente CA, McEvoy JD, Finkelstein D, Wei L, Kang G, Wang YD, Neale G, Ragsdale S, Valentine V, Bahrami A, Temirov J, Pounds S, Zhang J, Dyer MA. Benavente CA, et al. Oncotarget. 2013 Jun;4(6):844-59. doi: 10.18632/oncotarget.1051. Oncotarget. 2013. PMID: 23765217 Free PMC article.
  • Genetics and epigenetics of human retinoblastoma.
    Benavente CA, Dyer MA. Benavente CA, et al. Annu Rev Pathol. 2015;10:547-62. doi: 10.1146/annurev-pathol-012414-040259. Annu Rev Pathol. 2015. PMID: 25621664 Review.
  • Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma.
    Pritchard EM, Dyer MA, Guy RK. Pritchard EM, et al. Mini Rev Med Chem. 2016;16(6):430-54. doi: 10.2174/1389557515666150722100610. Mini Rev Med Chem. 2016. PMID: 26202204 Free PMC article. Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Friend SH, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature. 1986;323:643–646. - PubMed
    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674. - PubMed
    1. Knudson A. Mutation and Cancer:statistical study of retinoblastoma. PNAS. 1971;68:820–823. - PMC - PubMed
    1. Manning AL, Longworth MS, Dyson NJ. Loss of pRB causes centromere dysfunction and chromosomal instability. Genes & development. 2010;24:1364–1376. - PMC - PubMed
    1. Hernando E, et al. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature. 2004;430:797–802. - PubMed

Publication types

MeSH terms